TabletsClinical Overview
Second-generation sulfonylurea oral antidiabetic on the WHO Model List of Essential Medicines. Stimulates pancreatic beta-cell insulin secretion by blocking ATP-sensitive potassium channels. Indicated for type 2 diabetes mellitus.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally with breakfast or 30 minutes before the first main meal of the day with water. Never skip meals.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Hypoglycemia, weight gain, nausea, heartburn. Rare/Severe: Severe prolonged hypoglycemia (particularly with glibenclamide in elderly patients), cholestatic jaundice, and hematologic cytopenias.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Glibenclamide has an active metabolite that accumulates in renal impairment; high risk of fatal prolonged hypoglycemia in elderly patients (gliclazide or glimepiride preferred). Contraindicated in severe renal or hepatic impairment.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered endocrinologist, diabetologist, or qualified physician before initiating, adjusting dosages of, or substituting any antidiabetic or hormonal medication.
Glibenclamide Tablets 5 mg
Second-generation sulfonylurea oral antidiabetic on the WHO Model List of Essential Medicines. Stimulates pancreatic beta-cell insulin secretion by blocking ATP-sensitive potassium channels. Indicated for type 2 diabetes mellitus.
Glibenclamide 5mg + Metformin Hydrochloride 500mg Tablets
Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).
Glibenclamide 5 mg + Metformin 500 mg + Pioglitazone 15 mg Tablet
Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).